Head and Neck Cancer Research
Nivolumab Improves Survival for Patients with Recurrent Head and Neck CancerPosted: January 4, 2017
Results from a phase III trial showed that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.
FDA Approves Nivolumab for Head and Neck CancerPosted: December 1, 2016
The FDA has approved nivolumab for squamous cell carcinoma of the head and neck that has progressed during chemotherapy with a platinum-based drug or that has recurred or metastasized after platinum-based chemotherapy.
FDA Approves Pembrolizumab for Head and Neck CancerPosted: August 24, 2016
The approval is for patients with recurrent or metastatic head and neck squamous cell carcinoma that has continued to progress despite standard treatment with chemotherapy.
PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck CancerPosted: May 20, 2016
Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance after chemoradiation had overall survival rates similar to those of patients who underwent planned neck dissection and chemoradiation. But PET-CT imaging resulted in fewer operations and was more cost-effective than neck dissection.
Prospective Study Links HPV Detection in the Mouth to Head and Neck CancerPosted: February 12, 2016
A new study confirms that infection with HPV 16 precedes the development of head and neck cancer.
Genome Study Yields Clues to Head and Neck CancersPosted: February 3, 2015
Researchers have surveyed the genetic changes in nearly 300 head and neck cancers, revealing some previously unknown alterations that may play a role in the disease, including in patients whose cancer is associated with the human papillomavirus (HPV).
NIH-funded study uncovers range of molecular alterations in head and neck cancers, new potential drug targets; TCGA tumor genome sequencing analyses offer new insights into the effects of HPV and smokingPosted: January 28, 2015
Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences – with potentially important clinical implications – in head and neck cancers caused by infection with the human papillomavirus (HPV).
Worldwide trends show oropharyngeal cancer rates increasingPosted: November 20, 2013
NCI scientists report that the incidence of oropharyngeal cancer significantly increased during the period 1983-2002 among people in countries that are economically developed. Oropharyngeal cancer occurs primarily in the middle part of the throat behind the mouth, including the base of the tongue, the side and back walls of the throat, and the tonsils.
HPV vaccine shown to also protect against oral HPV infectionPosted: July 17, 2013
Costa Rican women who received a vaccine targeting two types of the HPV that cause 70 percent of cervical cancers had the added benefit of protection against oral HPV infection.
NIH scientists find promising biomarker for predicting HPV-related oropharynx cancerPosted: June 17, 2013
Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, which is a portion of the throat that contains the tonsils.